Beyondspring Inc

BYSI05 Dec 2024
Healthcare
$1.73
-0.02 (-1.74%)
Lowest Today
$1.68
Highest Today
$1.78
Today’s Open
$1.73
Prev. Close
$1.72
52 Week High
$4
52 Week Low
$0.78
To Invest in Beyondspring Inc

Beyondspring Inc

Healthcare
BYSI05 Dec 2024
-0.02 (-1.74%)
1M
3M
6M
1Y
5Y
Low
$1.68
Day’s Range
High
$1.78
1.68
52 Week Low
$0.78
52-Week Range
52 Week High
$4
0.78
1 Day
-
1 Week
-9.27%
1 month return
-16.19%
3 month return
-14.14%
6 month return
-30.43%
1 Year return
+99.56%
3 Years return
-56.96%
5 Years return
-87.18%
10 Years return
-
Institutional Holdings
Decheng Capital LLC
12.3
Citigroup Inc
0.62
BlackRock Inc
0.53
iShares Micro-Cap ETF
0.13
Tanaka Capital Management Inc
0.07
Fidelity Nasdaq Composite Index
0.06
Geode Capital Management, LLC
0.06

Market Status

Fundamentals
Market Cap
68.91 mln
PB Ratio
5.38
PE Ratio
0
Enterprise Value
57.43 mln
Total Assets
24.81 mln
Volume

Company Financials

Fund house & investment objective

Company Information
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.
Organisation
Beyondspring Inc
Employees
36
Industry
Biotechnology
CEO
Dr. Lan  Huang Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities